NEJM· Cary O. HardingOregon Health and Science University, PortlandNicola LongoUniversity of California, Los Angeles, Los AngelesMarkey McNuttUniversity of Texas Southwestern Medical Center, DallasRani H. SinghEmory University, AtlantaAndreu ViaderGeorge VratsanosHaoling H. WengElaina JureckiFernanda Leal-PardinasJnana Therapeutics, BostonWei LiOtsuka Pharmaceutical Development and Commercialization, Rockville, MDGuissou DabiriJohn P. ThroupJnana Therapeutics, BostonAnia C. Muntaufor the JNT517-101 Trial Investigators Group*University Medical Center Hamburg–Eppendorf, Hamburg, Germany·· 1 天前AI 评分58
NEJM：SLC6A19抑制剂Repinatrabit与苯丙酮尿症患者苯丙氨酸水平
SLC6A19 Inhibitor Repinatrabit and Phenylalanine Levels in Phenylketonuria
AI 导读
NEJM 刊出 JNT517-101 研究，评估 SLC6A19 抑制剂 Repinatrabit 对苯丙酮尿症患者苯丙氨酸水平的影响，作者来自 Oregon Health and Science University、Jnana Therapeutics 等机构。该文为 Volume 395 第 17 期的短篇报告，页码 1760-1763。
来源：NEJM · nejm.org